Skip to main content
Elsevier
View Cart
Your Account

Books in Neuropharmacology

BooksJournals

A Review on Diverse Neurological Disorders

  • 1st Edition
  • June 5, 2024
  • Rameshwar Nath Chaurasia + 2 more
  • English
  • eBook
    9 7 8 - 0 - 3 2 3 - 9 5 7 3 6 - 6
A Review of Diverse Neurological Disorders: Pathophysiology, Molecular Mechanisms, and Therapeutics offers an unparalleled compilation of the current understanding of neurodegenerative disorders. This book investigates the origins of mental disorders, encompassing bacterial and fungal invasions, viral assaults, and genetic predispositions, providing readers with a thorough grasp of the neurological landscape. Each chapter dissects the intricacies of these incapacitating conditions, ranging from the pathogenesis of central nervous system tuberculosis to the involvement of endocannabinoids in rabies infection. Topics such as neuroinflammation, axonal pathology, and the intricate relationship between diet, gut microbiomes, and cognitive decline are also explored. This book conducts an extensive examination of neurodegeneration, incorporating discussions on the role of probiotics and natural bioactive compounds in preventing ailments such as Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS). With meticulous analyses of vitamins, micronutrients, antioxidants, and nutraceuticals, this work offers a roadmap for promoting neuroprotection. A Review of Diverse Neurological Disorders serves as a resource that not only reviews the current understanding but also lays the groundwork for future treatments and innovations.

Nanomedicine-Based Approaches for the Treatment of Dementia

  • 1st Edition
  • October 11, 2022
  • Umesh Gupta + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 8 2 4 3 3 1 - 2
  • eBook
    9 7 8 - 0 - 3 2 3 - 8 5 9 0 6 - 6
Nanomedicine-Based Approaches for the Treatment of Dementia explores a wide range of promising approaches for the diagnosis and treatment of dementia. The book begins with introductory sections on dementia and brain ailments that are followed by further chapters that discuss detailed information about challenges of drug delivery across the blood-brain barrier as well as the current status. This book helps readers design and develop novel drug delivery systems and devices for the treatment of dementia that take advantage of recent advances in nanomedical technologies. Numerous drug delivery systems have been developed recently for dementia. Unfortunately, most of them are ineffective since dementia is not a single disease. It is an umbrella term for several neurodegenerative conditions which alter brain functions. Due to this, there is an urgent need for innovative technologies/nano drug delivery systems to improve the targeting and delivery of therapeutic as well as diagnostic agents specifically for treating dementia.

Novel Psychoactive Substances

  • 2nd Edition
  • September 6, 2021
  • Paul I. Dargan + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 1 8 7 8 8 - 3
  • eBook
    9 7 8 - 0 - 1 2 - 8 1 9 0 3 0 - 2
Novel Psychoactive Substances: Classification, Pharmacology and Toxicology, Second Edition provides readers with a comprehensive examination on the classification, detection, supply and availability of novel psychoactive substances, otherwise known as "legal highs." The book covers individual classes of novel psychoactive substances that have recently emerged onto the recreational drug scene and provides an overview of the pharmacology of the substance and a discussion of their associated acute and chronic harm and toxicity. This second edition addresses drugs new to the scene, with completely updated and revised chapters. Written by international experts in the field, this multi-authored book is an essential reference for scientists, clinicians, academics, and regulatory and law enforcement professionals.

Clinical Studies and Therapies in Parkinson's Disease

  • 1st Edition
  • June 12, 2021
  • Juan Segura-Aguilar
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 8 2 2 1 2 0 - 4
  • eBook
    9 7 8 - 0 - 1 2 - 8 2 2 1 5 8 - 7
More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson’s disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4–6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson’s disease, but these efforts have failed　when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow or halt development of the disease.Clinical Studies and Therapies in Parkinson’s Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book’s discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine.

Translational Medicine in CNS Drug Development

  • 1st Edition
  • Volume 29
  • June 18, 2019
  • George G. Nomikos + 1 more
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 0 3 1 6 1 - 2
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 3 1 6 4 - 3
Translational Medicine in CNS Drug Development, Volume 29, is the first book of its kind to offer a comprehensive overview of the latest developments in translational medicine and biomarker techniques. With extensive coverage on all aspects of biomarkers and personalized medicine, and numerous chapters devoted to the best strategies for developing drugs that target specific disorders, this book presents an essential reference for researchers in neuroscience and pharmacology who need the most up-to-date techniques for the successful development of drugs to treat central nervous system disorders. Despite increases in the number of individuals suffering from CNS-related disorders, the development and approval of drugs for their treatment have been hampered by inefficiencies in advancing compounds from preclinical discovery to the clinic. However, in the past decades, game-changing strides have been made in our understanding of the pathophysiology of CNS disorders and the relationship of drug exposure in plasma and CNS to pharmacodynamic measures in both animals and humans.

The Behavioral, Molecular, Pharmacological, and Clinical Basis of the Sleep-Wake Cycle

  • 1st Edition
  • March 26, 2019
  • Eric Murillo-Rodriguez
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 1 6 4 3 0 - 3
  • eBook
    9 7 8 - 0 - 1 2 - 8 1 6 7 4 2 - 7
The Behavioral, Molecular, Pharmacological, and Clinical Basis of the Sleep-Wake Cycle provides the first comprehensive overview on the molecular methodologies used to evaluate sleep while also examining the cellular, biochemical, genetic, and therapeutic aspects of the sleep-wake cycle. There have been profound changes in the landscape of approaches to the study of sleep – mainly in the areas of molecular biology and molecular techniques. With this great focus on using multidisciplinary molecular methods, chapters address significant advances in the molecular mechanisms underlying sleep and the techniques researchers use to study this phenomenon. Written by world-leading experts in the area, this book is of great interest to researchers working in the sleep field and to anyone interested in one of the most mysterious phenomena in science – why we sleep and why we cannot survive without it.

Brain Targeted Drug Delivery Systems

  • 1st Edition
  • September 20, 2018
  • Huile Gao + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 8 1 4 0 0 1 - 7
  • eBook
    9 7 8 - 0 - 1 2 - 8 1 4 0 0 2 - 4
Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates provides a guide on nanoparticulates to both academic and industry researchers. The book discusses key points in the development of brain targeted drug delivery, summarizes available strategies, and considers the main problems and pitfalls evidenced in current studies on brain targeted drug delivery systems. As the brain is the most important organ in the human body, and disorders of the central nervous system (CNS) are the most serious threat to human life, this book highlights advances and new research in drug delivery methods to the brain.

A Paradigm Shift to Prevent and Treat Alzheimer's Disease

  • 1st Edition
  • July 18, 2017
  • Howard Friel + 1 more
  • English
  • Paperback
    9 7 8 - 0 - 1 2 - 8 1 2 2 5 9 - 4
  • eBook
    9 7 8 - 0 - 1 2 - 8 1 2 2 7 9 - 2
A Paradigm Shift to Prevent and Treat Alzheimer’s Disease: From Monotargeting Pharmaceuticals to Pleiotropic Plant Polyphenols is the first book to systematically exhibit the powerful pleiotropic pharmacological effects on Alzheimer’s disease of plant-based compounds from ancient foods that humans have been consuming safely with substantial health benefits for thousands of years. These plant-based compounds include curcuminoids from turmeric, resveratrol from red wine and grape seed extract from other grape products, epigallocatechin-gallate (EGCG) from green tea, and oleocanthal and oleuropein from olive oil, in addition to a special extract, EGb 761, from the leaves of Ginkgo biloba, the oldest living species of tree on earth. This book also presents a new analytical framework that convincingly favors a multi-targeting ("pleiotropic") approach to the prevention and treatment of complex chronic diseases, in contrast to the mono-targeting of the pharmaceutical model. A Paradigm Shift to Prevent and Treat Alzheimer’s Disease is a unique and exciting resource for pharmaceutical scientists, pharmacologists, neurologists, general practitioners, research scientists in various medical and life sciences, healthcare professionals in clinical and executive positions, conventional medical schools, schools of naturopathic medicine, healthcare and medical journalists, executives in both national public healthcare systems and private insurers, and informed general readers.

Handbook of Cannabis and Related Pathologies

  • 1st Edition
  • December 31, 2016
  • Victor R Preedy
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 0 0 7 5 6 - 3
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 0 8 2 7 - 0
Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment is the first book to take an interdisciplinary approach to the understanding of cannabis use and misuse. Recent worldwide trends toward decriminalizing marijuana for medical use have increased legal use of the drug and recreational use remains high, making cannabis one of the most commonly used drugs. Cannabis has a wide range of adverse neurological effects, and use and abuse can lead to physical, social, and psychopathological issues that are multifarious and complex. Effective understanding and treatment requires knowledge of the drug’s effects from across scientific disciplines. This book provides an overview of the biological and pharmacological components of the cannabis plant, outlines its neurological, social, and psychopathological effects, assists in the diagnosis and screening for use and dependency, and aids researchers in developing effective treatments for cannabis-related issues and disorders. Fully illustrated, with contributions from internationally recognized experts, it is the go-to resource for neuroscientists, pharmacologists, pathologists, public-health workers, and any other researcher who needs an in-depth and cross-disciplinary understanding of cannabis and its effects.

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders

  • 1st Edition
  • September 20, 2016
  • Adeboye Adejare
  • English
  • Hardback
    9 7 8 - 0 - 1 2 - 8 0 2 8 1 0 - 0
  • eBook
    9 7 8 - 0 - 1 2 - 8 0 2 8 1 1 - 7
Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer’s Disease and illustrating the paradigm necessary to ensure future research and treatment success. The book explores diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer’s Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. It illustrates why these drugs tend to fail at the clinical stage, and examines Alzheimer’s Disease within the overall context of improving the drug discovery process for the treatment of other neurodegenerative disorders.